Literature DB >> 31362775

Vitamin C administration in the critically ill: a summary of recent meta-analyses.

Anitra C Carr1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31362775      PMCID: PMC6664573          DOI: 10.1186/s13054-019-2538-y

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
Since 2018, there has been a dramatic upsurge in publications relating to the use of vitamin C in critically ill patients, particularly those suffering from sepsis [1]. This has primarily been in response to the well-publicized before-and-after study of Marik et al. [2], which indicated that intravenous administration of 6 g/day vitamin C (in combination with thiamine and hydrocortisone) could improve the outcomes of patients with sepsis, including decreasing mortality. Over the past year, seven meta-analyses assessing the effects of vitamin C administration in critically ill patients have been published, with four appearing in the past 4 months alone (see Table 1 summary).
Table 1

A summary of recent meta-analysis of vitamin C administration in critical care patients

Publication detailsTitleSelection criteria (PICO)Included studiesSubgroup analysisFindings

Putzu et al. [3]

Crit Care Med

The effect of vitamin C on clinical outcome in critically ill patients: A systematic review with meta-analysis of randomised controlled trials

P—adult critically ill patients

I—vitC (any regimen)

C—placebo or no therapy

O—mortality, acute kidney injury, supraventricular arrhythmia, ventricular arrhythmia, stroke, ICU LOS, hospital LOS

44 RCTs:

16 in ICU setting (n = 2857)

28 in cardiac surgery (n = 3598)

Mixed ICU vs burns vs sepsis/septic shock vs acute pancreatitis

VitC alone vs enteral vitC vs IV vitC vs IV vitC > 5 g

ICU patients:

X mortality

X acute kidney injury

X ICU or hospital LOS

Cardiac surgery:

↓ postoperative atrial fibrillation

↓ ICU and hospital LOS

Wang et al. [4]

Ann Intensive Care

Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis

P—critically ill patients

I—IV vitC (including co-administration of antioxidants)

C—placebo or no intervention

O—mortality, resuscitation fluid requirement, urine output, acute kidney injury, vasopressor requirement, duration of mechanical ventilation, ICU and/or hospital LOS

12 RCT, quasi-RCT, observational (n = 1210)

Low dose vs medium dose vs high dose

Burn vs sepsis vs others

↓ mortality (doses of 3–10 g/day)

X morality (< 3 g/day or ≥ 10 g/day)

↓ duration of vasopressor support

↓ duration of mechanical ventilation

X acute kidney injury

X ICU or hospital LOS

X fluid requirement

X urine output

Hemila and Chalker [5]Vitamin C can shorten the length of stay in the ICU: A meta-analysis

P—ICU patients

I—vitC

C—placebo or none

O—ICU LOS, duration of mechanical ventilation

18 controlled trials (n = 2004)

including 13 cardiac surgery

IV vs oral

1–2 days ICU vs 3–5 days ICU

> 24 h ventilation vs < 24 h ventilation

↓ ICU LOS

↓ duration of mechanical ventilation

Langlois et al. [6]

JPEN

Vitamin C supplementation in the critically ill: A systematic review and meta-analysis

P—ICU patients

I—vitC (enteral or parenteral)

C—placebo or none

O—mortality, incident infections, ICU LOS, hospital LOS, duration of mechanical ventilation

11 RCTs

9 RCTs with mortality (n = 1322)

Low dose vs high dose

Combined therapy vs monotherapy

Oral/enteral vs parenteral

Non-septic vs septic

Higher-quality trials vs low-quality trials

X mortality

↓ (trend) mortality (IV high dose vitC monotherapy)

X infections

X ICU or hospital LOS

X duration of mechanical ventilation

Zhang and Jativa [7]

SAGE Open Med

Vitamin C supplementation in the critically ill: A systematic review and meta-analysis

P—critically ill adult patients

I—IV vitC

C—placebo or no intervention

O—mortality, duration of mechanical ventilation, duration of vasopressor support, fluid requirements, urine output

4 RCTs and 1 retrospective (n = 142)

X mortality

↓ need for vasopressor support

↓ duration of mechanical ventilation

↓ (trend) fluid requirements

↑ (trend) urine output

Li

Crit Care [1]

Evidence is stronger than you think: a meta-analysis of vitamin C use in patients with sepsis

P—patients with sepsis

I—IV vitC

C—placebo or none

O—mortality, ICU LOS, vasopressor duration

2 RCTs and 1 before-after

↓ mortality

X ICU LOS

↓ vasopressor duration

Lin et al. [8]

Open J Intern Med

Adjuvant administration of vitamin C improves mortality of patients with sepsis and septic shock: A systems review and meta-analysis

P—patients with septic shock and severe sepsis

I—vitC

C—placebo

O—mortality

4 RCTs and 2 retrospective studies (n = 109)

RCT vs retrospective

High dose vs low dose

X mortality

↓ mortality (doses of > 50 mg/kg/day)

X ICU LOS

ICU intensive care unit, IV intravenous, LOS length of stay, PICO patients, intervention, comparator, outcome, RCT randomized controlled trial, vitC vitamin C

A summary of recent meta-analysis of vitamin C administration in critical care patients Putzu et al. [3] Crit Care Med P—adult critically ill patients I—vitC (any regimen) C—placebo or no therapy O—mortality, acute kidney injury, supraventricular arrhythmia, ventricular arrhythmia, stroke, ICU LOS, hospital LOS 44 RCTs: 16 in ICU setting (n = 2857) 28 in cardiac surgery (n = 3598) Mixed ICU vs burns vs sepsis/septic shock vs acute pancreatitis VitC alone vs enteral vitC vs IV vitC vs IV vitC > 5 g ICU patients: X mortality X acute kidney injury X ICU or hospital LOS Cardiac surgery: ↓ postoperative atrial fibrillation ↓ ICU and hospital LOS Wang et al. [4] Ann Intensive Care P—critically ill patients I—IV vitC (including co-administration of antioxidants) C—placebo or no intervention O—mortality, resuscitation fluid requirement, urine output, acute kidney injury, vasopressor requirement, duration of mechanical ventilation, ICU and/or hospital LOS Low dose vs medium dose vs high dose Burn vs sepsis vs others ↓ mortality (doses of 3–10 g/day) X morality (< 3 g/day or ≥ 10 g/day) ↓ duration of vasopressor support ↓ duration of mechanical ventilation X acute kidney injury X ICU or hospital LOS X fluid requirement X urine output P—ICU patients I—vitC C—placebo or none O—ICU LOS, duration of mechanical ventilation 18 controlled trials (n = 2004) including 13 cardiac surgery IV vs oral 1–2 days ICU vs 3–5 days ICU > 24 h ventilation vs < 24 h ventilation ↓ ICU LOS ↓ duration of mechanical ventilation Langlois et al. [6] JPEN P—ICU patients I—vitC (enteral or parenteral) C—placebo or none O—mortality, incident infections, ICU LOS, hospital LOS, duration of mechanical ventilation 11 RCTs 9 RCTs with mortality (n = 1322) Low dose vs high dose Combined therapy vs monotherapy Oral/enteral vs parenteral Non-septic vs septic Higher-quality trials vs low-quality trials X mortality ↓ (trend) mortality (IV high dose vitC monotherapy) X infections X ICU or hospital LOS X duration of mechanical ventilation Zhang and Jativa [7] SAGE Open Med P—critically ill adult patients I—IV vitC C—placebo or no intervention O—mortality, duration of mechanical ventilation, duration of vasopressor support, fluid requirements, urine output X mortality ↓ need for vasopressor support ↓ duration of mechanical ventilation ↓ (trend) fluid requirements ↑ (trend) urine output Li Crit Care [1] P—patients with sepsis I—IV vitC C—placebo or none O—mortality, ICU LOS, vasopressor duration ↓ mortality X ICU LOS ↓ vasopressor duration Lin et al. [8] Open J Intern Med P—patients with septic shock and severe sepsis I—vitC C—placebo O—mortality RCT vs retrospective High dose vs low dose X mortality ↓ mortality (doses of > 50 mg/kg/day) X ICU LOS ICU intensive care unit, IV intravenous, LOS length of stay, PICO patients, intervention, comparator, outcome, RCT randomized controlled trial, vitC vitamin C The most recently published and largest meta-analysis included 44 randomized controlled trials (16 intensive care and 28 cardiac surgery) [9]. Although meta-analyses that include a larger number of studies have increased power, they run the risk of comparing disparate studies. This is particularly the case with vitamin C studies whereby the dose (milligrams vs grams), rout of administration (oral vs intravenous), duration (hours vs days), and disease (e.g., sepsis vs cardiac surgery) can have a large impact on outcomes [10, 11]. Therefore, appropriate subgroup analyses should be carried out, although this is currently challenging due to the low number of comparable studies. All but one of the current meta-analyses have focused on mortality as a primary outcome, despite many of the included trials having relatively low numbers of patients. In most cases, no effect of intervention was observed on mortality, except in specific subgroup analyses (e.g., sepsis and higher dose intravenous vitamin C). However, there have been few of these studies published to date, and even fewer of high methodological quality [6]. Other commonly assessed outcomes included ICU and hospital length of stay, duration of vasopressor support and mechanical ventilation, and acute kidney injury. Some of the meta-analyses showed decreases in several of these secondary outcomes, while others showed no effect, depending on the selection criteria used for study inclusion (Table 1). There are currently over a dozen randomized controlled trials registered on clinicaltrials.gov that are assessing the effects of vitamin C administration in critically ill patients, particularly those with sepsis. One would hope that in the short term, no more meta-analyses appear every time another small study is published, but instead wait until some of the larger trials (such as VICTAS and LOVIT) have been completed. Otherwise, there may end up with more meta-analyses than published trials.
  8 in total

1.  Understanding Vitamin C in Critical Illness: A Focus on Dose, Route, and Disease.

Authors:  Michael H Hooper; David N Hager
Journal:  Crit Care Med       Date:  2019-06       Impact factor: 7.598

2.  The Effect of Vitamin C on Clinical Outcome in Critically Ill Patients: A Systematic Review With Meta-Analysis of Randomized Controlled Trials.

Authors:  Alessandro Putzu; Anne-Marie Daems; Juan Carlos Lopez-Delgado; Vito Federico Giordano; Giovanni Landoni
Journal:  Crit Care Med       Date:  2019-06       Impact factor: 7.598

3.  Vitamin C Administration to the Critically Ill: A Systematic Review and Meta-Analysis.

Authors:  Pascal L Langlois; William Manzanares; Neill K J Adhikari; François Lamontagne; Christian Stoppe; Aileen Hill; Daren K Heyland
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-11-19       Impact factor: 4.016

4.  Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.

Authors:  Paul E Marik; Vikramjit Khangoora; Racquel Rivera; Michael H Hooper; John Catravas
Journal:  Chest       Date:  2016-12-06       Impact factor: 9.410

Review 5.  Vitamin C supplementation in the critically ill: A systematic review and meta-analysis.

Authors:  Michael Zhang; David F Jativa
Journal:  SAGE Open Med       Date:  2018-10-19

Review 6.  Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis.

Authors:  Ying Wang; Huan Lin; Bing-Wen Lin; Jian-Dong Lin
Journal:  Ann Intensive Care       Date:  2019-05-20       Impact factor: 6.925

7.  Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis.

Authors:  Harri Hemilä; Elizabeth Chalker
Journal:  Nutrients       Date:  2019-03-27       Impact factor: 5.717

8.  Evidence is stronger than you think: a meta-analysis of vitamin C use in patients with sepsis.

Authors:  Jing Li
Journal:  Crit Care       Date:  2018-10-11       Impact factor: 9.097

  8 in total
  11 in total

1.  Any Role of High-Dose Vitamin C for Septic Shock in 2021?

Authors:  Ankita Agarwal; David N Hager; Jonathan E Sevransky
Journal:  Semin Respir Crit Care Med       Date:  2021-09-20       Impact factor: 3.921

Review 2.  Dietary Supplements for COVID-19.

Authors:  Gerard E Mullin; Berkeley Limektkai; Lin Wang; Patrick Hanaway; Loren Marks; Edward Giovannucci
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Never a rose without a prick: pseudohyperglycemia when administering high-dose intravenous vitamin C.

Authors:  Yongli Zhang; Wei Huang
Journal:  Crit Care       Date:  2020-05-24       Impact factor: 9.097

4.  Mortality in septic patients treated with vitamin C: a systematic meta-analysis.

Authors:  Sean S Scholz; Rainer Borgstedt; Nicole Ebeling; Leoni C Menzel; Gerrit Jansen; Sebastian Rehberg
Journal:  Crit Care       Date:  2021-01-06       Impact factor: 9.097

5.  Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.

Authors:  Saeidreza JamaliMoghadamSiahkali; Besharat Zarezade; Sogol Koolaji; SeyedAhmad SeyedAlinaghi; Abolfazl Zendehdel; Mohammad Tabarestani; Ehsan Sekhavati Moghadam; Ladan Abbasian; Seyed Ali Dehghan Manshadi; Mohamadreza Salehi; Malihe Hasannezhad; Sara Ghaderkhani; Mohsen Meidani; Faeze Salahshour; Fatemeh Jafari; Navid Manafi; Fereshteh Ghiasvand
Journal:  Eur J Med Res       Date:  2021-02-11       Impact factor: 2.175

6.  Effect of adjunctive vitamin C, glucocorticoids, and vitamin B1 on longer-term mortality in adults with sepsis or septic shock: a systematic review and a component network meta-analysis.

Authors:  Tomoko Fujii; Georgia Salanti; Alessandro Belletti; Rinaldo Bellomo; Anitra Carr; Toshi A Furukawa; Nora Luethi; Yan Luo; Alessandro Putzu; Chiara Sartini; Yasushi Tsujimoto; Andrew A Udy; Fumitaka Yanase; Paul J Young
Journal:  Intensive Care Med       Date:  2021-11-09       Impact factor: 17.440

7.  Intravenous vitamin C administration to patients with septic shock: a pilot randomised controlled trial.

Authors:  Patrice Rosengrave; Emma Spencer; Jonathan Williman; Jan Mehrtens; Stacey Morgan; Tara Doyle; Kymbalee Van Der Heyden; Anna Morris; Geoff Shaw; Anitra C Carr
Journal:  Crit Care       Date:  2022-01-25       Impact factor: 9.097

Review 8.  Vitamins, supplements and COVID-19: a review of currently available evidence.

Authors:  Lauren L Speakman; Sarah M Michienzi; Melissa E Badowski
Journal:  Drugs Context       Date:  2021-10-06

Review 9.  Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework.

Authors:  Sebastià Galmés; Francisca Serra; Andreu Palou
Journal:  Nutrients       Date:  2020-09-08       Impact factor: 5.717

Review 10.  Implications of Vitamins in COVID-19 Prevention and Treatment through Immunomodulatory and Anti-Oxidative Mechanisms.

Authors:  Juan M Toledano; Jorge Moreno-Fernandez; María Puche-Juarez; Julio J Ochoa; Javier Diaz-Castro
Journal:  Antioxidants (Basel)       Date:  2021-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.